How to turn R&D data into a strategic asset with FAIR

The Life Sciences industry runs on data. But if that data is trapped in silos, it’s like running a marathon in flip-flops. 🩴 Enter Data Fabric: a smart layer that connects what you already have, and makes it work harder, faster, smarter. 🚀 We break it down in our latest blog → https://lnkd.in/dUaeWisR #Pharma #Biotech #ClinicalTrials #DataFabric

Solve the Data Puzzle for Life Sciences with Data Fabric. Great insight. Have a look into this blog by Pramod Sachdeva

What if data is the return on investment in a life sciences meeting? Data is often seen as something that can demonstrate ROI (and it is!), but the right data can also be one of the best things you get from a meeting. This article highlights how to leverage meeting metrics to gain information to guide future training, improve drug development, and help with strategic decision-making. https://hubs.ly/Q03LVly40 #lifesciences #meetingmetrics #investigatormeetings #CME

Less manual work. More decision-ready insights. 💬 “I’m one of the biggest advocates for Within3… it’s so much less I have to do.” In complex, competitive markets, #pharma success hinges on clarity, speed, and decisive action. Within3 brings together your most critical data sources into one real-time view — so teams can align faster, adapt instantly, and act with confidence. Learn more about turning your data into decision-ready insights: https://hubs.la/Q03KsL8r0 #data #lifesciences #launchexcellence #pharmalaunch #medicalaffairs

𝗔𝗜 𝗰𝗮𝗻 𝘀𝗶𝗺𝘂𝗹𝗮𝘁𝗲 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻𝘀, 𝗯𝘂𝘁 𝗰𝗮𝗻 𝗶𝘁 𝘀𝗶𝗺𝘂𝗹𝗮𝘁𝗲 𝗰𝗿𝗲𝗱𝗶𝗯𝗶𝗹𝗶𝘁𝘆? Synthetic respondents are reshaping how market research gets done, faster, cheaper, and smarter. But what’s their role - replace or amplify human voices, or speed up iteration processes? Explore our new whitepaper “Synthetic Respondents in Pharma: Opportunity to Fill Gaps, within Guardrails,” authored by Aritra Das, Nishant Agarwal, and Rajan Dua. 🔗Click here to learn more: https://lnkd.in/g-h59Zns #SyntheticRespondents #AIinPharma #DataDrivenInsights #PharmaInnovation #ProcDNA

Over the years, I’ve definitely seen how hard it is to get a clear view of data when systems are fragmented and teams are working in isolation. But it doesn't have to be that way. And a good first step includes mapping how data actually moves through the ecosystem, identifying who owns it, where it intersects, and where it stalls. When you can get to a shared visibility, and understanding of where things area really at, then even it at its most complex, your data turns into something you can work with. We see this all the time - and we can help.

Too many biopharma data teams run as "analysis-as-a-service". It's fast, but it caps organizational impact. Teams stay perpetually "busy", yet the company doesn't get systematically smarter. ✔️ What we should be doing instead is building a durable data backbone that compounds value throughout organization. Teams that focus only on executing analyses remain tactical contributors. Teams that design and operate a backbone become strategic multipliers for R&D. In my recent Medium article I break down the "how" (link in comments). If you want a 90-day transformation plan for your data team, reach out. #biotech #biopharma #datastrategy #drugdevelopment

Too many biopharma data teams run as "analysis-as-a-service". It's fast, but it caps organizational impact. Teams stay perpetually "busy", yet the company doesn't get systematically smarter. ✔️ What we should be doing instead is building a durable data backbone that compounds value throughout organization. Teams that focus only on executing analyses remain tactical contributors. Teams that design and operate a backbone become strategic multipliers for R&D. In my recent Medium article I break down the "how". If you want a 90-day transformation plan for your data team, reach out. #biotech #biopharma #datastrategy #drugdevelopment

Clinical metadata management is the backbone of reliable drug development. But when Biogen brought data management in-house, manual processes for CDASH, SDTM, and ADaM were slowing their 100+ global studies. Certara’s Pinnacle 21 Enterprise platform changed that. With an intuitive interface and seamless 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲𝗶𝗿 𝗥𝗮𝘃𝗲 𝗘𝗗𝗖 𝘀𝘆𝘀𝘁𝗲𝗺, Biogen transformed how they manage metadata, boosting efficiency and scalability. As Todd Bazin, Head, Data Standards at Biogen, explains: "𝘛𝘩𝘦 𝘶𝘴𝘦𝘳 𝘪𝘯𝘵𝘦𝘳𝘧𝘢𝘤𝘦 𝘰𝘧𝘧𝘦𝘳𝘦𝘥 𝘢𝘥𝘷𝘢𝘯𝘵𝘢𝘨𝘦𝘴, 𝘢𝘯𝘥 𝘪𝘵 𝘸𝘢𝘴 𝘧𝘶𝘯 𝘵𝘰 𝘸𝘰𝘳𝘬 𝘸𝘪𝘵𝘩. 𝘠𝘰𝘶 𝘤𝘢𝘯 𝘣𝘶𝘪𝘭𝘥 𝘵𝘩𝘦 𝘧𝘰𝘳𝘮𝘴 𝘢𝘯𝘥 𝘤𝘳𝘦𝘢𝘵𝘦 𝘷𝘪𝘴𝘶𝘢𝘭𝘪𝘻𝘢𝘵𝘪𝘰𝘯𝘴 𝘰𝘧 𝘸𝘩𝘢𝘵 𝘺𝘰𝘶'𝘷𝘦 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘦𝘥, 𝘵𝘰 𝘧𝘢𝘤𝘪𝘭𝘪𝘵𝘢𝘵𝘦 𝘴𝘵𝘢𝘬𝘦𝘩𝘰𝘭𝘥𝘦𝘳 𝘳𝘦𝘷𝘪𝘦𝘸𝘴 𝘦𝘢𝘳𝘭𝘺 𝘰𝘯." 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗰𝗮𝘀𝗲 𝘀𝘁𝘂𝗱𝘆 𝗵𝗲𝗿𝗲: https://ow.ly/3eHy50X0kah #Certara #Pinnacle21 #MetadataManagement #DataStandards

In biotech labs, data lives in the LIMS Conversations often live everywhere else That disconnect slows down projects and creates confusion. That’s why we help biotech teams build Contextual Chat inside the LIMS - a dedicated discussion space for every sample, project, protocol or material. ✅ Notes and updates stay with the data ✅ Attachments and results never get lost ✅ Approvals and pinned messages are always traceable ✅ Mentions and notifications keep the right people in the loop Fewer errors and clearer accountability. This is how we help our biotech clients reduce daily friction - so they can focus on what matters most: the science. We break it down in our latest article in the series “Custom LIMS Features for Hidden Lab Pains” Read here: https://lnkd.in/djevp5Z3